Cargando…

Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial

OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Keulen, Judit KJ, Bruinsma, Aafke, Kortekaas, Joep C, van Dillen, Jeroen, Bossuyt, Patrick MM, Oudijk, Martijn A, Duijnhoven, Ruben G, van Kaam, Anton H, Vandenbussche, Frank PHA, van der Post, Joris AM, Mol, Ben Willem, de Miranda, Esteriek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598648/
https://www.ncbi.nlm.nih.gov/pubmed/30786997
http://dx.doi.org/10.1136/bmj.l344
_version_ 1783430817457897472
author Keulen, Judit KJ
Bruinsma, Aafke
Kortekaas, Joep C
van Dillen, Jeroen
Bossuyt, Patrick MM
Oudijk, Martijn A
Duijnhoven, Ruben G
van Kaam, Anton H
Vandenbussche, Frank PHA
van der Post, Joris AM
Mol, Ben Willem
de Miranda, Esteriek
author_facet Keulen, Judit KJ
Bruinsma, Aafke
Kortekaas, Joep C
van Dillen, Jeroen
Bossuyt, Patrick MM
Oudijk, Martijn A
Duijnhoven, Ruben G
van Kaam, Anton H
Vandenbussche, Frank PHA
van der Post, Joris AM
Mol, Ben Willem
de Miranda, Esteriek
author_sort Keulen, Judit KJ
collection PubMed
description OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS: 1801 low risk women with an uncomplicated singleton pregnancy: randomised to induction (n=900) or to expectant management until 42 weeks (n=901). INTERVENTIONS: Induction at 41 weeks or expectant management until 42 weeks with induction if necessary. PRIMARY OUTCOME MEASURES: Primary outcome was a composite of perinatal mortality and neonatal morbidity (Apgar score <7 at five minutes, arterial pH <7.05, meconium aspiration syndrome, plexus brachialis injury, intracranial haemorrhage, and admission to a neonatal intensive care unit (NICU). Secondary outcomes included maternal outcomes and mode of delivery. The null hypothesis that expectant management is inferior to induction was tested with a non-inferiority margin of 2%. RESULTS: Median gestational age at delivery was 41 weeks+0 days (interquartile range 41 weeks+0 days-41 weeks+1 day) for the induction group and 41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) for the expectant management group. The primary outcome was analysed for both the intention-to-treat population and the per protocol population. In the induction group, 15/900 (1.7%) women had an adverse perinatal outcome versus 28/901 (3.1%) in the expectant management group (absolute risk difference −1.4%, 95% confidence interval −2.9% to 0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score <7 at five minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score <4 at five minutes. One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths occurred. 3 (0.3%) neonates in the induction group versus 8 (0.9%) in the expectant management group were admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). No significant difference was found in composite adverse maternal outcomes (induction n=122 (13.6%) v expectant management n=102 (11.3%)) or in caesarean section rate (both groups n=97 (10.8%)). CONCLUSIONS: This study could not show non-inferiority of expectant management compared with induction of labour in women with uncomplicated pregnancies at 41 weeks; instead a significant difference of 1.4% was found for risk of adverse perinatal outcomes in favour of induction, although the chances of a good perinatal outcome were high with both strategies and the incidence of perinatal mortality, Apgar score <4 at five minutes, and NICU admission low. TRIAL REGISTRATION: Netherlands Trial Register NTR3431.
format Online
Article
Text
id pubmed-6598648
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-65986482019-07-18 Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial Keulen, Judit KJ Bruinsma, Aafke Kortekaas, Joep C van Dillen, Jeroen Bossuyt, Patrick MM Oudijk, Martijn A Duijnhoven, Ruben G van Kaam, Anton H Vandenbussche, Frank PHA van der Post, Joris AM Mol, Ben Willem de Miranda, Esteriek BMJ Research OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS: 1801 low risk women with an uncomplicated singleton pregnancy: randomised to induction (n=900) or to expectant management until 42 weeks (n=901). INTERVENTIONS: Induction at 41 weeks or expectant management until 42 weeks with induction if necessary. PRIMARY OUTCOME MEASURES: Primary outcome was a composite of perinatal mortality and neonatal morbidity (Apgar score <7 at five minutes, arterial pH <7.05, meconium aspiration syndrome, plexus brachialis injury, intracranial haemorrhage, and admission to a neonatal intensive care unit (NICU). Secondary outcomes included maternal outcomes and mode of delivery. The null hypothesis that expectant management is inferior to induction was tested with a non-inferiority margin of 2%. RESULTS: Median gestational age at delivery was 41 weeks+0 days (interquartile range 41 weeks+0 days-41 weeks+1 day) for the induction group and 41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) for the expectant management group. The primary outcome was analysed for both the intention-to-treat population and the per protocol population. In the induction group, 15/900 (1.7%) women had an adverse perinatal outcome versus 28/901 (3.1%) in the expectant management group (absolute risk difference −1.4%, 95% confidence interval −2.9% to 0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score <7 at five minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score <4 at five minutes. One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths occurred. 3 (0.3%) neonates in the induction group versus 8 (0.9%) in the expectant management group were admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). No significant difference was found in composite adverse maternal outcomes (induction n=122 (13.6%) v expectant management n=102 (11.3%)) or in caesarean section rate (both groups n=97 (10.8%)). CONCLUSIONS: This study could not show non-inferiority of expectant management compared with induction of labour in women with uncomplicated pregnancies at 41 weeks; instead a significant difference of 1.4% was found for risk of adverse perinatal outcomes in favour of induction, although the chances of a good perinatal outcome were high with both strategies and the incidence of perinatal mortality, Apgar score <4 at five minutes, and NICU admission low. TRIAL REGISTRATION: Netherlands Trial Register NTR3431. BMJ Publishing Group Ltd. 2019-02-20 /pmc/articles/PMC6598648/ /pubmed/30786997 http://dx.doi.org/10.1136/bmj.l344 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Keulen, Judit KJ
Bruinsma, Aafke
Kortekaas, Joep C
van Dillen, Jeroen
Bossuyt, Patrick MM
Oudijk, Martijn A
Duijnhoven, Ruben G
van Kaam, Anton H
Vandenbussche, Frank PHA
van der Post, Joris AM
Mol, Ben Willem
de Miranda, Esteriek
Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title_full Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title_fullStr Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title_full_unstemmed Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title_short Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
title_sort induction of labour at 41 weeks versus expectant management until 42 weeks (index): multicentre, randomised non-inferiority trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598648/
https://www.ncbi.nlm.nih.gov/pubmed/30786997
http://dx.doi.org/10.1136/bmj.l344
work_keys_str_mv AT keulenjuditkj inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT bruinsmaaafke inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT kortekaasjoepc inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT vandillenjeroen inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT bossuytpatrickmm inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT oudijkmartijna inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT duijnhovenrubeng inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT vankaamantonh inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT vandenbusschefrankpha inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT vanderpostjorisam inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT molbenwillem inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial
AT demirandaesteriek inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial